Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
nl003 (4 trials)
oprelvekin (Neumega) (1 trial)
inactivated influenza vaccine (2 trials)
thymosin beta-4 (2 trials)
Arterial Occlusive Diseases (Phase 3)
Ischemia (Phase 3)
Peripheral Arterial Disease (Phase 3)
Peripheral Vascular Diseases (Phase 3)
Thrombocytopenia (Phase 3)
Vascular Diseases (Phase 3)
Trials (9 total)
Trial APIs (4 total)